• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

TOBI Podhaler (tobramycin inhalation powder) for oral inhalation, 28 mg

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

April 2014

Summary View

6 ADVERSE REACTIONS

6.2 Post-Marketing Experience
  • added ... aphonia to nervous system disorders.

7 DRUG INTERACTIONS

  • TOBI Podhaler should not be administered concomitantly with intravenous mannitol

Patient Information

Tell your healthcare provider about ...

  • “water pills” (diuretics) such as Edecrin (ethacrynic acid), Lasix (furosemide), or intravenous mannitol